The results of the current study identified seven target genes of dehydrovomifoliol in NAFLD treatment, namely E2F1, MERTK, SOX17, MMP9, SULT2A1, VEGFA, and BLVRA. The gene discussed is SOX17; the disease is metabolic dysfunction-associated steatotic liver disease.